Innovations in Antibacterial Agents: Combating Resistance, Improving Efficacy and Exploring New Mechanisms
A special issue of Antibiotics (ISSN 2079-6382). This special issue belongs to the section "Novel Antimicrobial Agents".
Deadline for manuscript submissions: 30 April 2025 | Viewed by 791
Special Issue Editors
Interests: antibiotics; drug design; Mur ligases; cell wall; medicinal chemistry;peptidoglycan; computer-aided drug design; machine learning
Special Issues, Collections and Topics in MDPI journals
Interests: design and synthesis of low molecular inhibitors; inhibitors of bacterial cell wall; Mur enzymes; penicillin binding proteins; InhA inhibitors; DNA girase inhibitors; FtsZ inhibitors; enzymatic and antibacterial evaluation of compounds
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The inappropriate use of antibacterial agents has promoted the emergence of resistant strains of bacteria and poses a significant threat to public health. The pervasive problem of antimicrobial resistance (AMR) is exacerbating healthcare crises worldwide, leading to increased mortality rates and rising healthcare costs. According to the World Health Organization (WHO), antibiotic resistance could cause up to 10 million deaths a year worldwide by 2050. Research into new antibiotics is therefore urgently needed.
This Special Issue aims to present a broad spectrum of research in the field of medicinal chemistry of antibacterial compounds and we welcome manuscripts that address both traditional and computational drug design strategies, from target identification to the application of machine learning and the screening of diverse chemical libraries in the discovery processes. In terms of publication priorities, modern methods, including virulence factor inhibitors, nanoparticles, antimicrobial peptides, phage therapy, and antisense oligonucleotides, are at the forefront. Papers dealing with the design and synthesis of new classes of antibacterial agents that introduce novel mechanisms of action, as well as studies focusing on the chemical synthesis and optimization of existing antibacterial agents, whether semi-synthetic or fully synthetic, are also welcome.
We are keen to publish ground-breaking research on the design and development of novel antibacterial agents for human and veterinary medicine. Authors are encouraged to submit original papers or reviews covering all aspects of this important topic.
Dr. Rok Frlan
Dr. Martina Hrast
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- drug design
- synthesis of novel antibacterial agents
- computational chemistry
- repurposing of drugs
- novel antibacterial mechanisms
